Mechanism and preventive measures of proteasome inhibitors in the treatment of multiple myeloma-related cardiotoxicity
10.12354/j.issn.1000-8179.2025.20241706
- VernacularTitle:PIs治疗多发性骨髓瘤相关心脏毒性的机制及防治措施
- Author:
Cai GUOCHUN
1
;
Wang SHIXUAN
1
;
Li FEI
1
Author Information
1. 南昌大学第一附属医院血液科,江西省血液病临床医学研究中心,江西省血液系统疾病重点实验室(南昌市 330006)
- Publication Type:Journal Article
- Keywords:
multiple myeloma(MM);
proteasome inhibitors(PIs);
cardiovascular adverse events(CVAEs)
- From:
Chinese Journal of Clinical Oncology
2025;52(12):623-627
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma(MM)is a malignant plasma cell clonal disease and the second most common malignant tumor of the blood system,accounting for approximately 1%of all tumor diseases and 13%of hematologic cancers.In recent years,its incidence has shown an upward trend.The development of proteasome inhibitors(PIs),immunomodulatory drugs(IMiDs),and autologous hematopoietic stem cell transplantation(auto-HSCT)has greatly improved the efficacy and prognosis of patients with myeloma.Among these,the development and clinical application of PIs represents a major milestone.However,long-term clinical experiencehas revealed that patients with MM who used PIs may develop new heart diseases,such as hypertension,cardiac insufficiency,arrhythmia,and ischemic heart disease,especially those who used cafilzomib.The use of PIs increases the probability of adverse cardiovascular events(CVAEs).Owing to the significant heterogen-eity in the definition of cardiotoxic endpoints,the exclusion of high-risk patients in clinical trials and the detection and treatment of PI-re-lated CVAEs vary.Therefore,the lack of sufficient evidence-based medical data hinders the standardized diagnosis and treatment of PI-re-lated CVAEs.This review summarizes the relevant mechanisms and response measures of cardiovascular diseases induced by PIs.
